JASPER THERAPEUTICS, INC. Deferred Offering Costs
JASPER THERAPEUTICS, INC. (JSPR) had Deferred Offering Costs of $75.00 million as of 2023-12-31, per its 10-K filed 2024-03-05.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2024-03-05
- 2023-12-31: Deferred Offering Costs $75.00M.
- 2023-09-30: Deferred Offering Costs $75.00M.
- 2023-06-30: Deferred Offering Costs $75.00M.
- 2023-03-31: Deferred Offering Costs $75.00M.
| Period end | Deferred Offering Costs |
|---|---|
| 2023-12-31 | $75.00M 10-K · filed 2024-03-05 |
| 2023-09-30 | $75.00M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $75.00M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $75.00M 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |